![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Yale Launches Trial of Ibudilast for Severe COVID-19 Patients
Yale Launches Trial of Ibudilast for Severe COVID-19 Patients
![Yale logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Yale-logo.gif?t=1631046869&width=430)
April 27, 2020
Yale researchers will conduct a clinical trial to test asthma drug MN-166 (ibudilast) as a potential treatment for severe COVID-19 patients.
Ibudilast has been approved in Japan and Korea for treatment of asthma. The trial will evaluate the drug for treating acute respiratory distress syndrome, a lung condition developed by seriously ill COVID-19 patients.
The researchers will partner with California-based MedicNova for the trial. MedicNova was developing ibudilast for treatment of multiple sclerosis and neuroinflammation.
Upcoming Events
-
21Oct